A common anti-inflammatory drug, mesalamine, can replace the work of good bacteria in fighting the nasty fungus Candida albicans in the gut.
C. albicans, or candida, is known to cause yeast infections. In some cases, it develops into invasive candidiasis, a potentially fatal infection occurring mostly in patients with compromised immunity.
The researchers found that this fungus can’t grow without an oxygen supply. Their study in mice showed that mesalamine can maintain a low oxygen (hypoxia) environment that prevents fungal bloom in the gut.
Potentially deadly invasive candidiasis
The team studied how C. albicans colonizes the gut. The fungus, best known for causing vaginal yeast infections, is usually treated with a topical or oral antifungal without serious side effects. It also harmlessly lives in the gut of around 60% of people.
Yet, when the body’s immunity goes down due to cancer or chemotherapy, the fungus may grow beyond the colon and spread throughout the body. In such cases, the patient develops invasive candidiasis.
“Invasive candidiasis is a potentially deadly infection with a mortality rate of around 50%. That’s even with the best available treatment,” says Andreas Bäumler, a professor in the medical microbiology and immunology department at the University of California, Davis, and lead author of the study, published in the journal Cell Host & Microbe.
Patients with leukemia and other blood cancers may need to take antibiotics. This use may cause an imbalance in the gut’s microbial community. It reduces Clostridia, a group of bacteria that promotes resistance to fungi colonization in the gut. With less Clostridia, C. albicans grows and colonizes in the tract.
“A bloom of C. albicans in the gut during antibiotic therapy is the most common cause of candidemia in people treated for blood cancers,” Bäumler explains. Candidemia is the presence of fungi or yeast in the blood.
Gut fungus has a taste for sugar
Bäumler and his team wanted to understand the factors involved in antibiotic-induced colonization of C. albicans in the gut.
They first colonized germ-free mice with Candida to see what the fungus consumed to bloom and realized it really liked simple sugars, similar to those found in high-sugar diets. Then, they tested its growth in a Petri dish. They placed Candida with simple sugars in an aerobic (with oxygen) setting, and the fungi bloomed.
“A healthy gut has low oxygen. So, we repeated the test in a hypoxia setting,” Bäumler says. The fungi didn’t grow despite the presence of sugars. This meant oxygen is a necessary condition for Candida growth.
‘Faux biotics’
The team did a series of experiments that showed antibiotic use reduced Clostridia in the gut. Giving mice probiotics, such as Clostridia, prevented C. albicans from growing in the gut. Yet, probiotics can be killed by antibiotics and cancer therapy. For this reason, probiotics would not help patients with leukemia or other blood cancers.
“Probiotics are often not safe in patients at the highest risk for invasive candidiasis,” Bäumler says. “Finding a therapy that can function like probiotics but can endure the impact of cancer treatment and antibiotics was important.”
The team explored 5-aminosalicylic acid (5-ASA) as a safer way to control C. albicans in the gut. 5-ASA, also known as mesalamine, is an anti-inflammatory drug. It is used to treat inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis.
The researchers tested 5-ASA in mice treated with antibiotics. They found that the drug could replace the work of probiotics by preventing oxygen in the colon and C. albicans from expanding in the gut.
“Limiting oxygen in the gut by replacing the function of good bacteria could be a strategy for reducing invasive candidiasis,” Bäumler says. “Our study opens a totally new treatment option for fatal fungal infections, especially for patients with cancer. After all, fungi cannot become resistant against hypoxia.”
The team proposed the term “faux-biotics” to refer to products, such as 5-ASA, that mimic the function of probiotics like Clostridia.
Funding was provided by Microbiome Tri-institutional Partnership in Microbiome Research (TrIP) Seed funding, the Crohn’s and Colitis Foundation of America, Public Health Service Grants, and the National Institutes of Health.
Source: UC Davis
